← Leaderboards
Linda P Dwoskin
University Of Kentucky
$22,762,643
Attributed
$24,714,363
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$24,714,363 · 11
By mechanism
U01$8,942,824 · 3
U19$5,986,342 · 1
R01$5,470,073 · 2
T32$2,759,802 · 1
P50$565,953 · 1
K02$412,998 · 1
Top collaborators
- Paula J Bates3 shared
- Kevyn E Merten1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- John M Littleton$19,398,400
- Bradley Barth Keller$5,918,980
- Christopher Mark Norris$15,768,108
- Tamara L. Knox$420,658
- Dennis K Miller$71,112
Others in their field
Top investigators on “Nicotinic Receptors”
- Marina R. Picciotto · Yale University$25,752,267
- Henry A. Lester · California Institute Of Technology$20,487,222
- Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute$17,620,368
- Paul J Kenny · Icahn School Of Medicine At Mount Sinai$17,249,281
- Lindsay H Burns · Cassava Sciences, Inc$16,572,741
- Andrew R Tapper · Univ Of Massachusetts Med Sch Worcester$14,911,649
Research focus
Nicotinic ReceptorsDrug AbuseAnalogLeadDopamineTrainingDrug Design /Synthesis /ProductionDopamine TransporterMethamphetamineProgramsSiteSelf AdministrationStructureSliceCorpus Striatum StructureMetabolismEvaluationNovel TherapeuticsPharmaceutical PreparationsDrug KineticsExhibitsRattusCytosolAffinity
Grant awards (54)
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$958,204
U01 · FY2022 · HL · contact PI
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$967,861
U01 · FY2021 · HL · contact PI
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$977,377
U01 · FY2020 · HL · contact PI
Development of Novel Therapeutics for Methamphetamine Abuse$99,999
U01 · FY2020 · DA · contact PI
Administrative Supplement: Training in Drug Abuse Related Research$89,965
T32 · FY2020 · DA · contact PI
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$999,998
U01 · FY2019 · HL · contact PI
Development of Novel Therapeutics for Methamphetamine Abuse$839,154
U01 · FY2019 · DA · contact PI
Development of Novel Therapeutics for Methamphetamine Abuse$926,568
U01 · FY2018 · DA · contact PI
Training in Drug Abuse Related Research$320,811
T32 · FY2018 · DA · contact PI
Training in Drug Abuse Related Research$291,159
T32 · FY2017 · DA · contact PI
Training in Drug Abuse Related Research$1
T32 · FY2017 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$702,880
U01 · FY2016 · DA · contact PI
Training in Drug Abuse Related Research$402,588
T32 · FY2016 · DA · contact PI
Training and Pilot Core$112,364
P50 · FY2016 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$699,330
U01 · FY2015 · DA · contact PI
Training in Drug Abuse Related Research$324,411
T32 · FY2015 · DA · contact PI
Training and Pilot Core$117,628
P50 · FY2015 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$709,981
U01 · FY2014 · DA · contact PI
Training in Drug Abuse Related Research$218,540
T32 · FY2014 · DA · contact PI
Training and Pilot Core$113,500
P50 · FY2014 · DA · contact PI
Training in Drug Abuse Related Research$94,408
T32 · FY2014 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$519,904
U01 · FY2013 · DA · contact PI
Training in Drug Abuse Related Research$248,886
T32 · FY2013 · DA · contact PI
Training and Pilot Core$108,961
P50 · FY2013 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$541,568
U01 · FY2012 · DA · contact PI
Training in Drug Abuse Related Research$270,933
T32 · FY2012 · DA · contact PI
Training and Pilot Core$113,500
P50 · FY2012 · DA · contact PI
Training in Drug Abuse Related Research$250,358
T32 · FY2011 · DA · contact PI
Training in Drug Abuse Related Research$247,742
T32 · FY2010 · DA · contact PI
Development of Antagonists for M5 Muscarinic Acetylcholine Receptor$181,294
R03 · FY2010 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$1,027,710
R01 · FY2009 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$572,644
R01 · FY2009 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$545,671
R01 · FY2008 · DA · contact PI
Developmemt of Novel Treatments for Nicotine Addiction$1,290,333
U19 · FY2007 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$531,621
R01 · FY2007 · DA · contact PI
Developmemt of Novel Treatments for Nicotine Addiction$1,289,142
U19 · FY2006 · DA · contact PI
Development of Novel Therapies or Methamphetamine Abuse$521,412
R01 · FY2006 · DA · contact PI
Nicotinic Receptor Regulation of Dopamine Transporter$178,821
R21 · FY2006 · DA · contact PI
Developmemt of Novel Treatments for Nicotine Addiction$1,262,846
U19 · FY2005 · DA
Development of Novel Therapies or Methamphetamine Abuse$523,621
R01 · FY2005 · DA
Nicotinic Receptor Regulation of Dopamine Transporter$216,256
R21 · FY2005 · DA
Developmemt of Novel Treatments for Nicotine Addiction$1,114,939
U19 · FY2004 · DA
Developmemt of Novel Treatments for Nicotine Addiction$1,029,082
U19 · FY2003 · DA
DEVELOPMENT OF NOVEL THERAPIES FOR METHAMPHETAMINE ABUSE$339,717
R01 · FY2003 · DA
DEVELOPMENT OF SELECTIVE NICOTINIC RECEPTOR ANTAGONISTS$116,948
K02 · FY2003 · DA
DEVELOPMENT OF NOVEL THERAPIES FOR METHAMPHETAMINE ABUSE$350,821
R01 · FY2002 · DA
DEVELOPMENT OF SELECTIVE NICOTINIC RECEPTOR ANTAGONISTS$116,948
K02 · FY2002 · DA
DEVELOPMENT OF NOVEL THERAPIES FOR METHAMPHETAMINE ABUSE$289,600
R01 · FY2001 · DA
DEVELOPMENT OF SELECTIVE NICOTINIC RECEPTOR ANTAGONISTS$212,047
R01 · FY2001 · DA
DEVELOPMENT OF SELECTIVE NICOTINIC RECEPTOR ANTAGONISTS$96,474
K02 · FY2001 · DA
DEVELOPMENT OF NOVEL THERAPIES FOR METHAMPHETAMINE ABUSE$59,368
R01 · FY2001 · DA
DEVELOPMENT OF NOVEL THERAPIES FOR METHAMPHETAMINE ABUSE$289,967
R01 · FY2000 · DA
DEVELOPMENT OF SELECTIVE NICOTINIC RECEPTOR ANTAGONISTS$205,874
R01 · FY2000 · DA
DEVELOPMENT OF SELECTIVE NICOTINIC RECEPTOR ANTAGONISTS$82,628
K02 · FY2000 · DA